Orexo’s annual report for 2013 released
Orexo’s annual report for the 2013 fiscal year has been published and can be downloaded from the investor section of the company’s homepage www.orexo.com/ar/2013/en/. For further information, please contact:Beata Augenblick, Investor RelationsTel: +46-18 780 88 50, E-mail: ir@orexo.com About OrexoOrexo is a specialty pharmaceutical company with commercial operations in the United States and R&D in Sweden developing improved treatments using proprietary drug delivery technology. The company is commercializing its proprietary product, ZUBSOLV® (buprenorphine and naloxone),